Adaptive intensity-modulated radiotherapy with simultaneous integrated boost for stage III non-small cell lung cancer: Is a routine adaptation beneficial?

Concurrent chemoradiation is the standard of care prior to consolidative durvalumab for patients with inoperable stage III non-small cell lung cancer (NSCLC).[1,2] Radiation-induced toxicities, especially pneumonitis (RP), are the most important dose-limiting factors hindering dose escalation and further tumor control improvement.[3] Acute toxicities after radiotherapy are also a key factor for patients not eligible to receive consolidation immunotherapy.[4]Fig 1.

Source: Radiotherapy and Oncology - February 22, 2021 Category: Radiology Authors: Yinnan Meng, Wei Luo, Hailing Xu, Wei Wang, Suna Zhou, Xingni Tang, Zihong Li, Chao Zhou, Haihua Yang Tags: Guidelines Source Type: research